Trials / Completed
CompletedNCT03568331
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)
A Randomized, Double-Blind, Placebo-Controlled Efficacy Study of The Neurokinin-1 Receptor Antagonist VLY-686 in Patients With Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 375 (actual)
- Sponsor
- Vanda Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with atopic dermatitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tradipitant | Oral Capsule |
| DRUG | Placebo | Oral Capsule |
Timeline
- Start date
- 2018-07-09
- Primary completion
- 2019-12-27
- Completion
- 2019-12-27
- First posted
- 2018-06-26
- Last updated
- 2024-05-13
- Results posted
- 2024-05-13
Locations
70 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03568331. Inclusion in this directory is not an endorsement.